CD19 and acute lymphoblastic leukemia: Because ruxolitinib can suppress T cell-mediated immune responses, the combinatorial use of ruxolitinib and CD19 CAR-T cells for JAK pathway-mutated-ALL could jeopardize CAR-T cell function.